RT Journal Article
SR Electronic
T1 Multiparametric MRI of Early Tumor Response to Immune Checkpoint Blockade in Metastatic Melanoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21257127
DO 10.1101/2021.05.13.21257127
A1 Lau, Doreen
A1 McLean, Mary A.
A1 Priest, Andrew N.
A1 Gill, Andrew B.
A1 Scott, Francis
A1 Patterson, Ilse
A1 Carmo, Bruno
A1 Riemer, Frank
A1 Kaggie, Joshua D.
A1 Frary, Amy
A1 Milne, Doreen
A1 Booth, Catherine
A1 Lewis, Arthur
A1 Sulikowski, Michal
A1 Brown, Lee
A1 Lapointe, Jean-Martin
A1 Aloj, Luigi
A1 Graves, Martin J.
A1 Brindle, Kevin M.
A1 Corrie, Pippa G.
A1 Gallagher, Ferdia A.
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.13.21257127.abstract
AB Background Immune checkpoint inhibitors are now standard of care treatment for many cancers. Treatment failure in metastatic melanoma is often due to tumor heterogeneity not easily captured by conventional CT or tumor biopsy. The aim of this prospective study was to investigate early microstructural and functional changes within melanoma metastases following immune checkpoint blockade using multiparametric MRI.Methods Fifteen treatment-naïve metastatic melanoma patients (total 27 measurable target lesions) were imaged at baseline, and following three weeks and twelve weeks of treatment on immune checkpoint inhibitors using T2-weighted imaging, diffusion kurtosis imaging and dynamic contrast-enhanced MRI. Treatment timepoint changes in tumor cellularity, vascularity and heterogeneity within individual metastases were evaluated and correlated to the clinical outcome within each patient.Results Differential tumor growth kinetics in response to immune checkpoint blockade were measured in individual metastases within the same patient. Early detection of tumor cell death or cell loss measured by a significant increase in the apparent diffusivity Dapp (p < 0.05) was observed in both responding and pseudoprogressive lesions after three week of treatment. Tumor heterogeneity (apparent kurtosis Kapp) was consistently higher in the pseudoprogressive and true progressive lesions, compared to the responding lesions throughout the first twelve weeks of treatment. These preceded tumor regression and significant tumor vascularity changes (Ktrans, ve and vp) detected after twelve weeks of immunotherapy (p < 0.05).Conclusions Multiparametric MRI demonstrated potential for early detection of successful response to immunotherapy in metastatic melanoma.Competing Interest StatementNo conflict of interest to declare with respect to the content of this work. AL, MS, LB and JML are employees of AstraZeneca UK.Clinical Trial11/NE/0312Funding StatementThis project was supported by Cancer Research UK (CRUK; C19212/A16628, C19212/A911376), the CRUK Cambridge Centre (C9685/A25177), a Cambridge Commonwealth, European and International Trust PhD Scholarship, a European Institute of Innovation and Technology (EIT) health grant for Innovation for Personalised Cancer Medicine, the CRUK & Engineering and Physical Sciences Research Council (EPSRC) Cancer Imaging Centre in Cambridge and Manchester (C197/A16465), Cancer Core Europe, the European Institute of Innovation and Technology (EIT) and Addenbrookes Charitable Trust. This research was also supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (RG85317). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Health Research Authority North East Research Ethics Committee 11/NE/0312All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information. Data are available upon reasonable request. Data may be obtained from a third party and are not publicly available. Please contact the corresponding authors.